Erenumab Brand Name– Aimovig
What is Erenumab
Erenumab is an injectable selective calcitonin gene-related peptide (CGRP) receptor antagonist indicated for migraine prophylaxis in adults. In clinical trials of patients with episodic migraine, monthly migraine days were significantly reduced by 2.9 to 3.7 days from baseline at 3 to 6 months in erenumab-treated patients in comparison to placebo.
At month 3, erenumab-treated chronic migraine patients experienced a significant 6.6-day reduction in monthly migraine days from baseline vs. placebo.
A 50% or greater reduction in monthly migraine days was achieved by 39.7% to 50% of episodic migraineurs and 39.9% to 41.2% of chronic migraineurs who were treated with erenumab compared to 26.6% to 29.5% of episodic migraineurs and 23.5% of chronic migraineurs given placebo.
Indications
- migraine prophylaxis
Side Effects
- alopecia
- alopecia
- anaphylactic shock
- anaphylactoid reactions
- angioedema
- antibody formation
- arrhythmia exacerbation
- arthralgia
- cardiac arrest
- constipation
- depression
- erythema
- hypertension
- injection site reaction
- loss of consciousness
- muscle cramps
- musculoskeletal pain
- myalgia
- palpitations
- pruritus
- rash
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- hypertension
- latex hypersensitivity
- pregnancy
Interactions
There are no drug interactions associated with Erenumab products.
